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ORIGINAL ARTICLE
Finely Tuned Temporal and Spatial Delivery
of GDNF Promotes Enhanced Nerve Regeneration
in a Long Nerve Defect Model
Laura M. Marquardt, PhD,1 Xueping Ee, MD,2 Nisha Iyer, MS,1 Daniel Hunter,2 Susan E. Mackinnon, MD,2
Matthew D. Wood, PhD,2 and Shelly E. Sakiyama-Elbert, PhD1,2
The use of growth factors, such as glial cell line-derived neurotrophic factor (GDNF), for the treatment of
peripheral nerve injury has been useful in promoting axon survival and regeneration. Unfortunately, finding a
method that delivers the appropriate spatial and temporal release profile to promote functional recovery has
proven difficult. Some release methods result in burst release profiles too short to remain effective over the
regeneration period; however, prolonged exposure to GDNF can result in axonal entrapment at the site of
release. Thus, GDNF was delivered in both a spatially and temporally controlled manner using a two-phase
system comprised of an affinity-based release system and conditional lentiviral GDNF overexpression from
Schwann cells (SCs). Briefly, SCs were transduced with a tetracycline-inducible (Tet-On) GDNF over-
expressing lentivirus before transplantation. Three-centimeter acellular nerve allografts (ANAs) were modified
by injection of a GDNF-releasing fibrin scaffold under the epineurium and then used to bridge a 3 cm sciatic
nerve defect. To encourage growth past the ANA, GDNF-SCs were transplanted into the distal nerve and
doxycycline was administered for 4, 6, or 8 weeks to determine the optimal duration of GDNF expression in the
distal nerve. Live imaging and histomorphometric analysis determined that 6 weeks of doxycycline treatment
resulted in enhanced regeneration compared to 4 or 8 weeks. This enhanced regeneration resulted in increased
gastrocnemius and tibialis anterior muscle mass for animals receiving doxycycline for 6 weeks. The results of
this study demonstrate that strategies providing spatial and temporal control of delivery can improve axonal
regeneration and functional muscle reinnervation.
Introduction
Peripheral nerve injury (PNI) often results in signif-icant loss of motor and sensory function, even after
surgical intervention. For example, only 25% of patients
regain proper motor function, and less than 3% regain sensa-
tion.1 For injuries that result in significant damage, substantial
tissue may need to be trimmed for easier repair.2 The gold
standard for surgical repair is an autograft, in which minor
sensory nerves are sacrificed to bridge the nerve defect site.
Due to several negative side effects of using autografts (donor
site morbidity, multiple surgeries, risk of infection), research
has turned to alternative grafting strategies.2 A current clinical
option is acellular nerve allografts (ANAs), cadaveric donor
nerves that undergo decellularization to remove immunogenic
cellular components leaving the basal lamina and extracellular
matrix (ECM) proteins largely intact.2–4 The native nerve ar-
chitecture of ANAs has proven effective in promoting axon
regeneration, yet functional outcomes still remain inferior to
that of autografts in long gapmodels.5 ThusANAsmay need to
be modified using cell transplantation and/or growth factor
delivery to improve their regenerative capacity.
Glial cell line-derived neurotrophic factor (GDNF), a
member of the transforming growth factor-b superfamily, has
been found to promote survival of midbrain dopaminergic
neurons that are damaged in degenerative diseases, such as
Parkinson’s, and shown to improvemotoneuron survival.6,7 It
has also been used to target sensory neurons to alleviate pain
in cases of chronic denervation.8–10 Signaling through the
GDNF family receptor a1 and its coreceptor Ret tyrosine
kinase, GDNF increases neurite extension and survival of
motor and sensory neurons both in vitro and in vivo.11,12
Unfortunately, endogenous GDNF levels can decrease with
chronic denervation, which impedes regeneration.13 Thus, it
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is important to develop effective delivery strategies that tar-
get the site of injury and distal nerve to improve regeneration
and functional recovery.
Various strategies have been employed to deliver GDNF,
including diffusion-based, vehicle-based, gene-based, and
cell-based delivery. The simplest method to locally deliver
GDNF is passive diffusion from saline injections or growth
factor-soaked materials.14,15 However, protein drugs can
lose their efficacy over long regeneration periods due to de-
naturation or degradation. Affinity-based delivery systems
(ABDS) temporarily sequester growth factors within im-
planted matrices.16,17 For example, heparin-based delivery
systems (HBDS) use the ability of heparin to temporarily bind
to growth factors through electrostatic interactions17–20 and
protect them from degradation. As the scaffold is enzymati-
cally degraded by infiltrating cells and regenerating axon
growth cones, GDNF can be released and bound to receptors.
Delivery of GDNF from fibrin-filled silicone conduits using
an HBDS resulted in increased regeneration and functional
recovery compared to fibrin-alone.21,22 However, the HBDS
provides controlled release of GDNF over*2 weeks, which
is relatively short compared to the time required for regen-
eration across long nerve defects. Vehicle-based GDNF de-
livery using poly (lactic-co-glycolic acid) microspheres have
shown promise in nerve regeneration,23–25 yet this system
acts on a similar time scale as the ABDS.
Methods for long-term delivery include gene- or cell-based
delivery. Dorsal root ganglia (DRG) treated with cells trans-
fected with a GDNF lentiviral vector resulted in an increased
neurite outgrowth in vitro.26 Yet, when this GDNF lentivirus
was injected into injured nerves in vivo, regenerating axons did
not reach their target organs.26,27 Upon further inspection, it
was found that prolonged overexpression of GDNF entrapped
axons caused axonal swirling and coils and abnormal forma-
tion of myelin.26,28 The entrapment of axons was termed the
‘‘candy-store effect,’’ as regenerating axons are entrapped at
the site of GDNF production. Similar results were observed
when Schwann cells (SCs) constitutively overexpressingGDNF
were transplanted within ANAs.29
The goal of this study was to improve the regenerative ca-
pacity of ANAs by optimizing the spatial and temporal delivery
of GDNF. The GDNF release was regulated through transduc-
tion of SCswith a tetracycline-inducible GDNF, overexpressing
lentiviral vector. Through this mechanism, doxycycline ad-
ministration controls the duration of GDNF expression by SCs.
The bioactivity of GDNF released by SCs was confirmed
through an in vitro assay, and then the cells were transplanted in
an in vivo injury model. A 3-cm nerve gap was bridged using
ANAs injected with fibrin containing GDNF and HBDS, and
GDNF-SCs were transplanted into the distal nerve segment.
Rats were given doxycycline for 4, 6, or 8 weeks, and the op-
timal duration of GDNF expression was determined through
live imaging and histomorphometry of regenerating nerves. An
intermediate time point of 6 weeks reduced the candy-store
effect resulting in a total axon number in the distal nerve similar
to an isograft, indicating that temporal and spatial regulation of
delivery can improve regeneration.
Materials and Methods
All materials were purchased from Sigma Aldrich unless
otherwise noted.
Construction and production of lentiviral vector
The GDNF Tet-on and tdTomato (in vivo control vector)
vectors were made using similar established protocols.30
Briefly, DsRed cDNA sequence was amplified and inserted
into FCIV-GDNF (containing GDNF-IRES-Venus, from
Milbrandt Lab at Washington University) resulting in FCIV-
GDNF-IRES-DsRed. The GDNF-IRES-DsRed fragment
was excised and inserted into pEN-TRE-DsRed-PL (derived
from pEN_TRmiRc2, ATCC Catalog No. MBA-250), re-
sulting in pEN-TRE-GDNF-IRES-DsRed. The Hope Center
Viral Core at the Washington University School of Medi-
cine performed all viral vector design and production using
a standard 293T packing cell line.
SC isolation and viral vector transduction
SCs were isolated from adult male Sprague-Dawley sciatic
nerves as previously described.30 SCs were seeded at
1.5 · 104 cells/cm2 on poly-l-lysine-coated wells in a 24-well
plate and allowed to attach overnight. Cells were incubated
with 2 mg/mL polybrene (Santa Cruz Biotechnology) in cul-
ture media for 1 h and then the Tet-on GDNF-IRES-DsRed
viral vector was added at a multiplicity of infection (MOI) of
20 for 20 h.30 The DsRed fluorescent reporter was inserted
into the conditional GDNF vector to allow visualization of
transfected cells. SCs were washed in fresh culture media. To
confirm transduction, cells were cultured in 5mg/mL doxy-
cycline and imaged for DsRed fluorescence after 72–96 h. To
ensure similarity of fluorescence in transplanted cells, SCs
were sorted using fluorescence-activated cell sorting with a
MoFlo sorter (Beckman Coulter, Inc.) at the Siteman Flow
Cytometry Core (data not shown).
In vitro bioactivity assay
GDNF expression from GDNF-SCs and tdTomato-SCs
(in vivo control vector) was analyzed using a GDNF ELISA
Duoset kit (R&D Systems) according to previous methods.31
To confirm the GDNF bioactivity, Tet-on GDNF-SCs were
cocultured with dissociated E8 chick DRG in Transwell
plates (Corning) similar to previously described methods30
and neurite growth was compared to wild-type (WT) and
YFP-SC (in vitro bioactivity control vector) cocultures.
Fibrin matrix preparation
Fibrinogen solutions were made by dialyzing 8mg/mL
human plasminogen-free fibrinogen (EMD Bioscience) as
previously described.20 Fibrin matrices were prepared by
mixing the following components (at final concentration):
4mg/mL fibrinogen, 2.5mM CaCl2, 2 NIH U/mL thrombin,
0.25mM antithrombin III peptide,16,32 62.5 mM heparin, and
100 ng/mL recombinant human GDNF (Peprotech).
ANA decellularization and injection
Three-centimeter sciatic nerve grafts were harvested from
27 male Lewis rats for ANA processing. Sciatic nerves were
decellularized using previously established protocols.3,33
ANAs were injected with the fibrin-based HBDS for the
controlled release of GDNF adjacent to regenerating fibers
in the proximal nerve stump. All solutions were kept on ice
during injection to prevent premature gelation within the
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syringe. For each nerve graft, *80 mL of GDNF-HBDS fi-
brin was injected beneath the epineurium in 10mL volumes
using a 27-gauge Hamilton syringe as previously de-
scribed.34 Grafts were held immobilized during the injection
using drosophila fly pins, and the distal end was clamped
shut with a microvessel clamp to prevent leakage. Once
injected, nerves were placed in a 37C incubator for 30min
to allow fibrin polymerization before implantation.
Experimental design and surgical procedures
Adult male and female Thy1-GFP Sprague-Dawley rats
(Harlan Laboratories), weighing between 250–300 g, were
used.35 All surgical procedures and perioperative care
measures were performed in strict accordance with the
National Institutes of Health guidelines and were approved
by the Washington University Animal Studies Committee
(IACUC). All animals were housed in a central animal fa-
cility. After surgical procedures, animals recovered in a
warm environment and were closely monitored.
Fifty-one Thy1-GFP rats were randomized into eight
groups as shown in Table 1, and additional three rats were
used as donors for isograft controls. To administer doxy-
cycline, fresh water supply was supplemented with 1mg/mL
doxycycline every other day, and the rats drank ad libitum.
A representative schematic of GDNF delivery though the
GDNF HBDS and Tet-on GDNF SCs using doxycycline
administration for 6 weeks is shown in Figure 1A. Surgical
procedures were performed using the aseptic technique for
microsurgical dissection and repairs. Rats were anesthetized
with subcutaneous delivery of ketamine (75mg/kg; Fort
Dodge Animal Health) and dexmedetomidine (0.5mg/kg;
Pfizer Animal Health). Briefly, the hind leg was shaved and
prepped, and the sciatic nerve was exposed using a dorso-
lateral gluteal muscle-splitting incision. In all experimental
groups, the sciatic nerve was transected through the com-
mon peroneal and tibial nerves *5mm distal to the trifur-
cation, to spare the sural nerve and prevent autophagia. A
schematic of the surgical procedure is shown in Figure 1B.
In groups with transplanted SCs (tdTomato control vector or
GDNF-expressing), 1 · 106 SCs were injected beneath the
epineurium of the distal nerve stumps with 20 mL fibrin to
improve cell engraftment. Representative images of SCs, 2
weeks after transplantation in the distal nerve, are shown in
Figure 1C and D. Suturing reversed nerve grafts to the
proximal and distal nerve stumps using three to four 9-0
nylon sutures through the epineurium created a 3-cm critical
nerve gap. Wounds were closed with 5-0 vicryl sutures
through the muscle fascia and 4-0 nylon skin sutures. Over
the entire recovery period, the sciatic nerve was reexposed
every 2 weeks for live imaging.35 Once exposed, the rats
were placed under a mounted upright fluorescent micro-
scope and imaged using Micromanager software.36 After
imaging, the wounds were closed.
After 8 weeks of recovery, animals were again placed
under anesthesia, and the sciatic nerve was reexposed. The
nerve grafts were harvested with an additional 10-mm seg-
ment of native nerve taken proximally and distally. Midgraft
and distal tissue sections were removed and placed in 3%
glutaraldehyde solution in 0.1M phosphate buffer at 4C
until histomorphometric analysis. Animals were euthanized
with an intracardiac injection of Euthasol (150mg/kg)
(Delmarva Laboratories).
Histomorphometry
After distal and midgraft tissues were harvested and fixed,
they were postfixed with 1% osmium tetroxide, ethanol
dehydrated, and embedded in Araldite 502 (Polyscience,
Inc.) as previously described.37 Cross-sections were imaged
midgraft and distally at 1000· and analyzed by a blinded
observer for total axon count, axon density, percent neural
tissue, percent myelin debris, fiber width, and myelin width.
Quantitative real-time polymerase chain reaction
Distal nerve segments were stored in RNAlater, and then
mRNA was collected and purified using an RNeasy mini
prep kit (Qiagen). The purity and concentration of mRNA
were determined using a NanoPhotometer (Implen), and
mRNA was converted to cDNA using the High Capacity
mRNA-to-cDNA kit (Life Technologies). Gene expression
of GDNF and the housekeeping gene b-actin was deter-
mined using Taqman gene expression assays (Life Tech-
nologies) and Fast Master Mix (Life Technologies) on the
Step One Plus Real-Time PCR system.
Statistical analysis
All results are reported as mean – standard error of the
mean. The number of animals analyzed within each group is
indicated by ‘‘n’’ values. Statistical analysis was performed
using Statistica version 6 (Statsoft, Inc.). All data were
Table 1. Experimental Design for Tet-On GDNF Overexpression In Vivo Study
Group













I Isograft - - - + 8 6
II ANA - - - + 8 6
III GDNF delivery system (DS) - + - + 8 6
IV Control vector-SCs+GDNF DS - + 8 + 8 6
V GDNF-SCs Dox8 no GDNF DS + - 8 + 8 6
VI GDNF-SCs Dox4+GDNF DS + + 4 + 8 7
VII GDNF-SCs Dox6+GDNF DS + + 6 + 8 7
VIII GDNF-SCs Dox8+GDNF DS + + 8 + 8 7
ANA, acellular nerve allograft; GDNF, glial cell line-derived neurotrophic factor; HBDS, heparin-based delivery systems; SC, Schwann cells.
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evaluated for differences between groups using the analysis
of variance test with least-squared difference post hoc tests
with statistical significance set at a = 0.05 ( p < 0.05).
Results
Bioactivity of GDNF released from Tet-on GDNF SCs
For conditional long-term delivery of GDNF, SCs were
transduced with a doxycycline-inducible GDNF over-
expressing lentiviral vector (Fig. 2A). Transduction was
confirmed through image analysis of DsRed fluorescence
after activation of the tetracycline response element by
doxycycline (Fig. 2B). With an MOI of 20, the efficiency of
transduction was *100%. To test whether the GDNF ex-
pression was elevated compared to normal SCs, GDNF
expression in GDNF-SCs were compared to tdTomato-SCs
(in vivo control vector) using an ELISA. The GDNF ex-
pression in GDNF-SCs was significantly higher than the
control even after 2 days of doxycycline treatment (Fig. 2C).
To confirm the biological activity, GDNF-SCs, control
vector-SCs, and WT-SCs were cultured in Transwell plates
with dissociated DRG, and the neurite extension was mea-
sured after 18 h. As shown in Figure 2D, transduction of SCs
with the control vector had no effect on the neurite exten-
sion compared to WT-SCs, demonstrating that the trans-
fection process alone does not affect neurite outgrowth.
When neurons were cultured with GDNF-SCs, the neurite
extension was increased by *32% versus WT-SCs. These
results indicate that the level of biologically active GDNF
expressed by the SCs after transduction with the Tet-on
GDNF lentiviral vector increased in the presence of doxy-
cycline.
In addition to in vitro bioactivity, we also wanted to en-
sure that transplanted Tet-on GDNF-SCs continued to
overexpress GDNF in the distal nerve during doxycycline
administration. We performed quantitative real-time poly-
merase chain reaction on the distal nerve segments of con-
trol vector-SC and GDNF-SC transplanted groups at 4
FIG. 1. Representation of isograft and acellular nerve allograft (ANA) surgical procedure. (A) A representative schematic
of an intermediate glial cell line-derived neurotrophic factor (GDNF) delivery time point in which GDNF is released by both
heparin-based delivery systems (HBDS) and Tet-on GDNF Schwann cells (SCs) under 6 weeks of doxycycline induction. (B)
The sciatic nerve is exposed and separated after the trifurcation to spare the sural nerve. The common peroneal and tibial
nerves are transected*5mm distal to the trifurcation and a 3-cm reverse isograft or ANA is used to bridge the proximal and
distal nerve stumps. Three to four sutures were used to coapt the grafts to the host tissue. For animals receiving SCs, SCs were
injected beneath the epineurium distal to the graft area. Representative images are shown of the 3-cm GDNF-DS modified
ANA before grafting and immediately after. (C) tdTomato control vector and (D) merged GFP and tdTomato expression is
observed 2 weeks after injection into distal nerve stumps. Images are taken at 0.63· magnification. Red indicates control
vector-labeled SCs, green represents Thy1-GFP axons. Color images available online at www.liebertpub.com/tea
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weeks posttransplantation. GDNF mRNA levels are signif-
icantly upregulated in the distal nerve with Tet-on GDNF-
SCs compared to control vector-SCs (Fig. 2E). This result
demonstrates that with doxycycline, GDNF expression re-
mains elevated for at least 4 weeks in vivo.
Live tracking of regenerating axons
Live fluorescence imaging allows us to monitor re-
generating axons during the recovery period to see differ-
ences in the rate of regeneration and when axons become
entrapped. It also allows us to determine when the axon
front has reached the distal nerve so that we can shut off
GDNF expression to prevent trapping. As shown in Figure
3A, differences in GFP+ axon growth through the grafts can
be visualized at 8 weeks, indicating various regeneration
rates depending on the treatment group.
The length of GFP+ axon growth into the grafts for each
group is shown in Figure 3B. In addition, we examined the
length of GFP+ axons normalized to graft length as the
grafts can shrink with time (Fig. 3C). Early, there is little
difference between the experimental groups, although
groups with GDNF trend slightly higher than the (negative)
ANA control. Isograft controls (positive) have a signifi-
cantly increased rate and length of regeneration at all points;
however, when the GFP length was normalized to graft
length, there was no difference between isografts and ani-
mals with 6 weeks of GDNF overexpression. It is interesting
to note that the length of axons for GDNF-SCs given
doxycycline for 4 weeks (‘‘Dox4’’) stops increasing at the
same rate after 4 weeks, whereas doxycycline treatment for
6 (‘‘Dox6’’) and 8 weeks (‘‘Dox8’’) continued to increase. It
is not until week 8 that we observe axons with GDNF-SCs
given doxycycline the entire 8-week recovery period stop
regenerating. As indicated by Figure 3C, groups that re-
mained entrapped within the graft could be identified as
falling below the graft normalized length.
Histology
Qualitative assessment of nerve tissue distal to the grafts
was performed by light microscopy. Nerve organization and
architecture of the regenerating fibers can be observed and
differentiated between the different experimental and con-
trol groups (Fig. 4). Normal, uninjured nerve organization
can be classified as having compact uniformly arranged fi-
bers that are similar in size and shape. GDNF-DS and
GDNF-SCs-Dox6 had the most organized nerve architecture
similar to isograft-positive controls (Fig. 4C, G). A more
disorganized architecture was observed in ANA and control
vector-SCs groups. Groups with doxycycline removed too
early (4 weeks) or too late (8 weeks) had severely disor-
ganized nerve architecture with few axons randomly ar-
ranged.
Histomorphometry
At the end of the 8-week recovery period, the average
total axon fiber count for midgraft and distal nerve segments
was measured for each group, and isografts were found to
have the greatest fiber number (Fig. 5A, B). As predicted by
the live imaging data, the experimental group with GDNF-
SCs given doxycycline for 6 weeks had a total number of
FIG. 2. SCs were successfully transduced with a Tet-on GDNF LV vector. (A) A cartoon depiction of the Tet-on GDNF LV
vector shows GDNF expression induced with tetracycline (or its analog doxycycline). Tetracycline binds to the reverse tran-
scriptase activator (rtTA3), and then, together the tetracycline and rtTA3 activate the tetracycline response element (TRE) driving
GDNF andDsRed expression. (B)Merged bright-field and fluorescent image is shown of Tet-onGDNF-SCs just before injection.
(C)GDNF released from control vector-SCs and GDNF-SCs after doxycycline induction. (D)Average neurite length showed no
difference between wild-type (WT) and control vector-SCs. Neurite length significantly increased in cultures with GDNF over-
expressing SCs. Data are represented by the mean–SEM. * denotes statistical significance fromWT-SCs ( p< 0.05). (E)mRNA
was extracted from the distal nerve segments of GDNF-SC and control vector-SC-transplanted animals, andGDNFmRNA levels
were examined. Compared to control vector-SC animals, GDNF mRNA was almost 20-fold higher in the distal nerve segment
where SCs overexpressed GDNF. Dotted linemarks upregulation. Color images available online at www.liebertpub.com/tea
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axon fibers most similar to isografts. On the other hand,
when doxycycline was removed too early (4 weeks), or
maintained for the entire recovery period (8 weeks), re-
generating axons stopped before reaching the distal nerve.
GDNF-SC-Dox4+GDNF-DS, GDNF-SCs no GDNF-DS
Dox8, and GDNF-SC-Dox8+GDNF-DS groups had signifi-
cantly lower fiber counts in the midgraft and distal nerve
segments compared to isografts.
Of the control groups, ANAs modified with the GDNF-
DS were most similar to the isografts fiber number, whereas
the negative control (ANA alone) was significantly lower
(Fig. 5A, B). The addition of control vector-SCs to the distal
nerve in general appeared to improve the frequency of re-
generation, but the total axon number was only slightly
higher than the ANA alone. Overall, these results identify
treatment strategies for improving axon regeneration in long
critical nerve gaps. Clearly, the time and method of GDNF
delivery can have a significant effect on axons.
The axon fiber density was also measured for each group
in the midgraft and distal nerve and was significantly af-
fected by the duration of GDNF delivery (Fig. 5C, D).
Isograft controls had the highest nerve fiber density in the
distal nerve, although the GDNF-DS and GDNF-SC-
Dox6+GDNF-DS groups were not significantly different
(Fig. 5D). Interestingly, in the midgraft, axon density was
highest when GDNF was overexpressed by GDNF-SCs for 6
weeks (Fig. 5C). ANAs alone had significantly lower fiber
density compared to isografts in the distal nerve. GDNF
FIG. 3. Live imaging of GFP axons highlights differences in regeneration. (A) Fluorescent images of Thy1-GFP axons at
the end of the 8-week recovery period for the control and experimental conditions are shown. By the end of the recovery
period, regeneration of GFP+ axons past the graft area can be observed clearly in the isograft control group. The GDNF-DS
group also indicates distal growth of GFP+ axons, but regeneration appears greatly reduced in the ANA group and slightly
reduced in the control vector-SC group. When doxycycline was removed too early at 4 weeks or continued for the entire 8
weeks (with orwithout the GDNF-DS), GFP+ axons become entrappedwithin the graft. Only 6weeks of doxycycline showGFP+
axons past the distal suture line. White arrowheads denote start and end of graft region. Scale bar= 3mm. *denotes statistical
significance from all other groups. (B) Average length of GFP+ axons over the 8-week recovery period is shown. Isografts had
significantly greater length of GFP fluorescence over time. Only at 8 weeks does is stand out that DS ANA and GDNF-SCs DS
Dox6 promoted greater GFP+ axon extension into the grafts. Data are represented by the mean–SEM. ^ denotes significance
from GDNF-SCs DS Dox6 ( p< 0.05). (C) Length of GFP+ axons was normalized to the length of the grafts as the grafts can
shrink over time. The dotted line at 1 marks the growth of GFP+ axons at graft length and clearly identifies groups in which axons
become entrapped within the graft. Color images available online at www.liebertpub.com/tea
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expression for too short or too long a time led to decreased
fiber density distally.
To assess the quality of the regenerating nerve, we also
examined the percent neural tissue and percent myelin de-
bris (Fig. 6). There was little change in percent nerve tissue
in the midgraft nerve segment between groups; however, the
highest percent nerve was found in GDNF-SC Dox6 with
*19.5% (Fig. 6A). In the distal nerve, the percent nerve
tissue was highest for isografts, with GDNF-DS and GDNF-
SC-Dox6+GDNF-DS not significantly different from iso-
grafts (Fig. 6B). ANAs alone and those with control vector-
SCs were significantly lower, but it was the groups with
under- or over-GDNF expression that contain the lowest
percent of neural tissue. Normal uninjured nerves typically
containaround61%nerve tissue.These results inversely relate to
the percent myelin debris foundwithin the distal nerve segment.
The groups with the lowest percent neural tissue (GDNF-
SC-Dox4+GDNFDS and GDNF-SC-Dox8+/-GDNFDS) had
FIG. 4. Improved regeneration of
nerves by gross histology is observed
in DS ANA and GDNF-SC-Dox6
groups. Gross histology of sectioned
nerves indicates differences in regen-
eration between groups. Re-
presentative images for each group are
shown for (A) Isograft, (B) ANA, (C)
GDNF-DS, (D) control vector-SCs +
GDNF-DS, (E) GDNF-SC-Dox8 no
GDNF-DS, (F) GDNF-SCs GDNF-DS
Dox4, (G) GDNF-SCs GDNF-DS
Dox6, and (H) GDNF-SCs GDNF-DS
Dox8. Organized nerve architecture of
compact uniformly sized fibers can be
observed clearly in the isograft con-
trol. Similar morphology can be seen
in DS ANA and GDNF-SCs DS Dox6.
Delivery of GDNF for too short (4
weeks) or too long (8 weeks) a period
results in poor organization and tissue
‘‘swirling.’’ Scale bar= 5 mm. Color
images available online at www
.liebertpub.com/tea
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the highest amount of myelin debris (Fig. 6C, D). The
high amount of myelin debris is likely not the result of cell
transplantation, as both groups control vector-SCs and
GDNF-SC-Dox6 had myelin debris levels similar to that of
isografts.
Another measurement to assess the maturation of re-
generating fibers is the myelinated nerve fiber width. Mature
myelinated nerve fibers in an uninjured sciatic nerve are
*6.5mm in width. The myelinated fiber distribution varied
little between groups in both the midgraft and distal nerve
segments (Fig. 7A, B); however, the spread of fiber width was
influenced by whether midgraft or distal axons were analyzed.
Midgraft, there was a larger spread of fiber widths, whereas in
the distal nerve there were fewer large diameter fibers and the
percentage of fibers falling between 3–4mm increased. In this
study, it is important to note that only animals that had mea-
surable fibers were analyzed. Myelin width was also measured
and found to be similar between groups.
Muscle mass analysis
Muscle atrophy occurs in cases of long-term denervation
due to lack of neurotrophic activity and results in decreased
muscle fiber organization, muscle mass, and contractility.38
The degree of reinnervation correlates to the increase in
mass of the muscles affected by injury. In this study, we
measured the tibialis anterior (TA) and gastrocnemius (GA)
muscle mass at the end of the 8-week recovery period and
normalized these values to the unoperated contralateral
muscle. The isograft group showed a 60% decrease in GA
muscle mass compared to the unoperated control (Fig. 8A).
Only the group with GDNF-SCs and 6-week doxycycline
treatment was not significantly lower than the isograft,
suggesting a similar degree of reinnervation. Groups with
only 4 weeks of doxycycline or the entire 8 weeks of
doxycycline resulted in a 75–80% muscle mass decrease. As
with the GA muscle, only the isograft group was not sig-
nificantly different than GDNF-SC-Dox6 for the TA muscle,
for operated muscles were *38% and 42% of their un-
operated control muscles, respectively (Fig. 8B). The dif-
ferences observed between the muscles are likely attributed
to differences in regeneration of the common peroneal and
tibial nerves.
Discussion
The focus on repairing PNI has shifted in recent years
from a single mechanism of treatment toward combinatorial
FIG. 5. GDNF delivery from the
DS-modified ANA and 6 weeks of
GDNF overexpression improves
total axon number and axon den-
sity. Total number of axons in the
(A) midgraft and (B) distal nerve
sections for each group was quan-
tified. Axon density was quantified
in the (C) midgraft and (D) distal
nerve segments. Data are re-
presented by the mean – SEM
(n ‡ 6 animals per group). * denotes
statistical significance from isograft
( p < 0.05), ^ denotes significance
from DS ANA ( p < 0.05), and +
denotes significance from GDNF-
SCs DS Dox6 ( p < 0.05).
SPATIOTEMPORAL CONTROL OF GDNF DELIVERY ENHANCES NERVE REGENERATION 2859
approaches that seek to recapitulate aspects of native nerves
to obtain similar regeneration to autografts. Many groups
have designed nerve guidance conduits as bridging support
structures, yet they lack the microstructure found in native
tissue.39–41 One must take into account the physical struc-
ture of nerves, as well as any biochemical or cellular com-
ponents to fully mimic autograft regeneration. ANAs have
proven to be a clinically viable option because they provide
both the structure of endoneurial tubes and native ECM
components.33 Unfortunately, neurotrophic factors are lost
during decellularization, and poor results are seen in long
nerve defects (>3 cm).42 Cell transplantation therapies have
FIG. 6. The quality of nerve re-
generation was improved for DS-
modified ANA and 6 weeks of
GDNF overexpression. The percent
neural tissue in the (A) midgraft
and (B) distal nerve for each group
was quantified. The percent myelin
debris was quantified in the (C)
midgraft and (D) distal nerve seg-
ments. Data are represented by the
mean – SEM (n ‡ 6 animals per
group). * denotes statistical signif-
icance from isograft ( p < 0.05),
^ denotes significance from DS
( p < 0.05), and + denotes signifi-
cance from GDNF-SCs DS Dox6
( p < 0.05).
FIG. 7. The timing or method of GDNF delivery did not affect fiber width distribution. Distribution of the average fiber
width of regenerated fibers in the (A) midgraft and (B) distal nerve was quantified. Data are represented by the mean – SEM
(n ‡ 3 animals per group, animals with 0 regenerated fibers were not included).
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been shown to improve the regenerative capacity of ANAs,
yet remain inferior to that of isografts.5 Therefore, the ad-
dition of cells and/or growth factors, such as GDNF, may
improve the outcomes for ANAs in long gap nerve repairs.
In this study, we carefully designed a cell transplantation
and drug delivery platform to deliver GDNF to regenerating
axons in a spatially and temporally controlled manner. First,
GDNF was released adjacent to the proximal nerve stump
from a HBDS injected beneath the epineurium of a 3 cm
ANA to help jump start regenerating axons in the first 2
weeks of regeneration, as well as promote migration of
endogenous SCs into the graft. Second, sustained delivery of
GDNF from virally transduced SCs modified to condition-
ally overexpress GDNF in the distal nerve segment was used
to promote regeneration of axons into the distal nerve. The
main goal of this study was to determine how the timing of
GDNF overexpression from transplanted SCs could signif-
icantly impact the level of axonal regeneration.
Regulating the timing of GDNF delivery is critical to de-
veloping an effective therapy for functional regeneration.
Constitutive expression of GDNF through gene- or cell-based
delivery has led to the entrapment of axons.27,28 The term
‘‘candy-store effect’’ was coined due to the contentment of
axons to remain at the site of GDNF overexpression, where
there is a concentrated neurotrophic support. Tannemaat et al.
showed that the direct injection of GDNF lentiviral vectors led
to constant GDNF overexpression, and regenerating motor
axons never reached their target end organs.27,43 Others have
shown that GDNF-expressing SCs transplanted at the site of
injury failed to promote regeneration past themidgraft line and
limited functional recovery was observed.29,44 Transient
overexpression of GDNF from nonvirally transduced adipose-
derived stem cells in an injured ventral root model has shown
improved regeneration, however, the lack of a controlled
temporal expression mechanism prevents specific tuning for
various applications.45 Consequently, we wanted to design a
system in which GDNF expression can be turned off as re-
generating axons approach the site of GDNF production, al-
lowing axons growth through the site and reinnervating target
organs.
In this study, SCs were transduced with a conditional
tetracycline-inducible GDNF expressing lentiviral vector.
Upon doxycycline treatment, GDNF is overexpressed, but
can be turned off with the removal of doxycycline. The
results of the study demonstrated that fine-tuning the timing
of delivery significantly affects regeneration. When doxy-
cycline was removed too early (4 weeks), regenerating ax-
ons effectively stopped in their tracks. Only four animals out
of seven had any regeneration, and of those, the total
number of axons was very low. The exact mechanism of this
abrupt stop is unknown, but it could be due to the sudden
loss of a GDNF gradient. Conversely, 8 weeks of GDNF
overexpression led to poor outcomes, suggesting that axons
may be entrapped at or just before the site of GDNF pro-
duction. It was only with 6 weeks of GDNF overexpression
that axons were able to reach the distal nerve segment and
then continue on. Shakhbazau et al. reported a similar result,
in which constant GDNF expression led to regeneration
failure.46 However, after 1 week of GDNF expression, axons
with normal morphology were capable of extending past the
site of production. This shorter time window for optimal
expression was due to the difference in transplantation site
(midgraft in a 1.5-cm graft vs. distal to a 3-cm graft in our
study). Unfortunately, the former study only looked quali-
tatively at the regenerating axons and did not quantify how
well the grafts performed in histomorphometric analysis.
The transplantation of GDNF-expressing SCs also played
a role in the quality of nerve regeneration. The delivery of
GDNF from SCs for 6 weeks led to an improved percent
neural tissue and decreased myelin debris, while any other
duration of GDNF delivery led to an inferior quality of re-
generation. The percent neural tissue when GDNF was re-
leased for 4 or 8 weeks was significantly lower than all other
groups. Furthermore, the percent myelin debris was much
FIG. 8. Six weeks of GDNF overexpression from distally transplanted SCs leads to enhanced muscle mass recovery.
Percent muscle mass recovery of the (A) gastrocnemius muscle and (B) tibialis anterior muscle compared to the unoperated
control. Data are represented by the mean – SEM (n ‡ 6 animals per group). * denotes statistical significance from isograft
( p < 0.05), + denotes significance from GDNF-SCs DS Dox6 ( p< 0.05), and # denotes significance from all groups except
isograft ( p < 0.05).
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higher in these groups compared to the other groups.
Transplantation of exogenous SCs alone does not lead to
these results, as control vector-expressing SCs and GDNF-
SC-Dox6 were comparable to isografts in percent myelin
debris. Thus, these results are likely due to the breakdown of
regeneration caused by either abrupt removal of GDNF or
persistent GDNF expression. In a study by Hoyng et al.,
they found that the entrapment of axons at the site of con-
tinual GDNF overexpression led to a breakdown in nerve
structure with a high degree of abnormal SC morphology,
myelin debris, and axon swirling, similar to Figure 4.28,43
The axon regeneration results indicated by both live im-
aging and histomorphometry coincided with trends observed
in muscle mass.38 Specifically, the GDNF-SC-Dox6 group
had the highest percentage of muscle mass compared to all
of the groups for the TA muscle and was the most similar to
isograft controls in the GA muscle. While this test is not a
true quantification of functional muscle force recovery, the
increase in operated muscle mass indicates a high degree of
reinnervation and function as increased use leads to in-
creased mass. The significant improvement in muscle mass
of the GDNF-SC-Dox6 group is also impressive due to the
relatively short time of 8 weeks. Previous work has shown
improvement of muscle mass and grid grip tests from iso-
grafts at 8 weeks, but it took up to 12 weeks for improve-
ment in groups with GDNF released from the HBDS within
15-mm silicone conduits.21 It is also interesting to note that
while the control ANAs modified with the GDNF-DS had a
significant number of total regenerated axons, this did not
translate to an increased muscle mass. This could be due to
incorrect reinnervation (sensory axons innervating muscle
end organs) or the increase of sensory axon regeneration
over motor axons. GDNF is a known stimulant of sensory
neuron survival and regeneration, thus the early release from
the ANA may tend to target sensory axons.11,27,47
Conclusions
Previous work has shown that ANAs serving as an effective
platform for regeneration and transplantation of SCs further
improves their regenerative capacity, but they still lack the
neurotrophic support, such as GDNF, necessary to promote
functional regeneration across long nerve gaps. However, as
uncontrolled GDNF expression can actually impair regenera-
tion, careful spatial and temporal control of GDNF delivery
may help in developing a successful treatment strategy.
Therefore, we have designed and implemented a cell trans-
plantation and growth factor delivery paradigm where GDNF
is released in both a spatially and temporally controlled man-
ner from an affinity-based system and inducible SC over-
expression system. We have found that a finely tuned window
of time for GDNF overexpression results in increased axonal
regeneration and muscle mass recovery, whereas delivery for
too short a time arrests extending axons, while prolonged ex-
pression entraps axons. Live imaging analysis aided in iden-
tifying the position and time point at which GDNF
overexpression should be removed to encourage axons to reach
and reinnervate their target end organs.
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